Biodexa Pharmaceuticals annual total debt
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Total Debt Growth & History (BDRX)
Biodexa Pharmaceuticals's total debt was £61,000 for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual total debt history
| Fiscal year | Period ended | Total debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | £61,000 | −£548,000 | −89.98% |
| 2024 | 2024-12-31 | £609,000 | £440,000 | +260.36% |
| 2023 | 2023-12-31 | £169,000 | £8,000 | +4.97% |
| 2022 | 2022-12-31 | £161,000 | £15,000 | +10.27% |
| 2021 | 2021-12-31 | £146,000 | −£54,000 | −27.00% |
| 2020 | 2020-12-31 | £200,000 | −£212,000 | −51.46% |
| 2019 | 2019-12-31 | £412,000 | −£1.1M | −72.57% |
| 2018 | 2018-12-31 | £1.5M | −£5.0M | −77.05% |
| 2017 | 2017-12-31 | £6.5M | £4.4M | +203.34% |
| 2016 | 2016-12-31 | £2.2M | £208,000 | +10.67% |
| 2015 | 2015-12-31 | £1.9M | — | — |
Biodexa Pharmaceuticals quarterly total debt
Q4.18
Q4.19
Q4.20
Q4.21
Q4.22
Q2.23
Q4.23
Q2.24
Q4.24
Q2.25
Q4.25
| Fiscal quarter | Period ended | Total debt | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | £61,000 | −£548,000 | −89.98% |
| Q2 2025 | 2025-06-30 | £501,000 | £327,000 | +187.93% |
| Q4 2024 | 2024-12-31 | £609,000 | £440,000 | +260.36% |
| Q2 2024 | 2024-06-30 | £174,000 | £10,000 | +6.10% |
| Q4 2023 | 2023-12-31 | £169,000 | £8,000 | +4.97% |
| Q2 2023 | 2023-06-30 | £164,000 | — | — |
| Q4 2022 | 2022-12-31 | £161,000 | £15,000 | +10.27% |
| Q4 2021 | 2021-12-31 | £146,000 | −£54,000 | −27.00% |
| Q4 2020 | 2020-12-31 | £200,000 | −£212,000 | −51.46% |
| Q4 2019 | 2019-12-31 | £412,000 | −£1.1M | −72.57% |
| Q4 2018 | 2018-12-31 | £1.5M | — | — |
Biodexa Pharmaceuticals total debt trends
Over the last five fiscal years, Biodexa Pharmaceuticals's total debt decreased from £200,000 to £61,000, a change of −£139,000. The latest reported quarter, Q4 2025, shows £61,000.
About the metric
What total debt means
Total debt measures a company’s reported interest-bearing borrowing obligations at a reporting-period end. It can include short-term borrowings, current maturities, long-term debt, and finance lease obligations when they are included in the company’s debt facts.
Calculation and source
SEC-reported and combined total debt
TickerStat uses a reported aggregate debt value when available. Otherwise, it combines non-overlapping current and noncurrent debt facts from SEC filings. Total liabilities are not treated as debt, and missing debt is not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...